Abstract: Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.
Type:
Grant
Filed:
June 8, 2020
Date of Patent:
February 17, 2026
Assignee:
ADIMAB, LLC
Inventors:
Robert Pejchal, Caitlin Stein, Julia McCreary
Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
January 20, 2026
Assignee:
Adimab, LLC
Inventors:
Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
April 18, 2023
Date of Patent:
April 15, 2025
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
Abstract: A method of broadening epitopic coverage of an antigen of interest, wherein a first sample of the antigen of interest is contacted with a first plurality of host cells collectively expressing a first library of antibodies. Host cells expressing antibodies that bind to the antigen are then collected from among the first plurality of host cells, and a composition is prepared comprising a polyclonal mixture of antibodies expressed by these host cells. A second sample of the antigen of interest is then contacted with an aliquot of the prepared composition and a second plurality of host cells collectively expressing a second library of antibodies. Host cells expressing antibodies that bind to the second sample of the antigen are then collected from among the second plurality of host cells.
Type:
Grant
Filed:
June 13, 2022
Date of Patent:
March 25, 2025
Assignee:
Adimab, LLC
Inventors:
Laura M. Walker, Eric Krauland, Karl Dane Wittrup
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
January 28, 2025
Assignees:
Biopharmaceutical, Inc., Albert Einstein College of Medicine, Adimab, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Multispecific antibody analogs that co-engage at least two different antigens or epitopes, which may also be referred to as targets as used interchangeably throughout, said analogs comprising a common light chain, are provided, as well as methods for their production and use.
Abstract: The present invention relates, inter alia, to polyspecificity reagents, methods of making the same, and methods of using the same in, inter alia, the selection, screening, enrichment, and identification of non-polyspecific, and thus developable, polypeptides.
Type:
Grant
Filed:
December 3, 2020
Date of Patent:
December 31, 2024
Assignee:
Adimab, LLC
Inventors:
Piotr Bobrowicz, Amber D. Hanna, Jerry M. Thomas
Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
June 25, 2024
Assignee:
Adimab, LLC
Inventors:
Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Application
Filed:
April 18, 2023
Publication date:
September 14, 2023
Applicants:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
May 30, 2023
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
January 3, 2023
Assignee:
Adimab, LLC
Inventors:
Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
November 1, 2022
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
October 25, 2022
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
August 9, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
August 9, 2022
Assignees:
MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
Inventors:
Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Z. Wec, Laura Walker
Abstract: A method of broadening epitopic coverage of an antigen of interest, wherein a first sample of the antigen of interest is contacted with a first plurality of host cells collectively expressing a first library of antibodies. Host cells expressing antibodies that bind to the antigen are then collected from among the first plurality of host cells, and a composition is prepared comprising a polyclonal mixture of antibodies expressed by these host cells. A second sample of the antigen of interest is then contacted with an aliquot of the prepared composition and a second plurality of host cells collectively expressing a second library of antibodies. Host cells expressing antibodies that bind to the second sample of the antigen are then collected from among the second plurality of host cells.
Type:
Grant
Filed:
April 9, 2020
Date of Patent:
July 19, 2022
Assignee:
Adimab, LLC
Inventors:
Laura M. Walker, Eric Krauland, Karl Dane Wittrup